Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    NEXT STORY
    Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
    PREV STORY
    OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    NEXT STORY
    Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
    PREV STORY
    OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting

    author_avatar
    NASDAQ Market News

    Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI

    —Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in ...

    author_avatar
    NASDAQ Market News

    Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission

    SAN DIEGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News